X-396 capsule

DRUG2 trials

Sponsors

Betta Pharmaceuticals Co., Ltd.

Conditions

Lung CancerNon-Small Cell Lung CancerROS1 Gene Rearrangement

Phase 2

X-396 Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib

Betta Pharmaceuticals Co., Ltd.Non-Small Cell Lung Cancer

Start: 2017-09-28End: 2023-12-31Target: 152Updated: 2023-08-16

X-396 Capsule in Advanced NSCLC Patients With ROS1 Gene Rearrangement

Betta Pharmaceuticals Co., Ltd.Lung Cancer, ROS1 Gene Rearrangement

Start: 2018-06-15End: 2020-09-30Target: 69Updated: 2020-01-09

Related Papers

Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib‐refractory <i>ALK</i> ‐positive NSCLC from a phase II study

Cancer Communications2024-02-297 citations

ROS1-positive non-small-cell lung cancer

Cancer Research Statistics and Treatment2022-07-0111 citations

Safety but Limited Efficacy of Ensartinib in ROS1-Positive NSCLC: A Single-Arm, Multicenter Phase 2 Study.

2021-07-1213 citations

Abstract 2997: Longitudinal circulating tumor DNA (ctDNA) analysis predicts response and reveals the resistance mechanisms of ensartinib in ALK+ NSCLC patients (pts) progressed on crizotinib: Updated analysis of a phase II clinical trial

Cancer Research2020-08-154 citations

Ipsilateral breast metastasis from lung adenocarcinoma harboring anaplastic lymphoma kinase or ROS1 rearrangement and significant response after targeted therapy: report of two cases

Chinese Medical Journal2020-06-161 citations

Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial.

2019-10-15107 citations

Ensartinib (X-396), a second-generation ALK TKI, in Chinese ALK-positive non-small cell lung cancer: A phase I, dose-escalation study.

Journal of Clinical Oncology2018-05-205 citations